Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 5/20 | 0.48 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773558 | 0.91 | GPR119 (0.58) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL70696 | 0.88 | GPR119 (0.60) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2160959 | 0.88 | RBP4 (0.47) | GPR119PDE4BSCD | |
| SCHEMBL22265825 | 0.87 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6113438 | 0.86 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL72738 | 0.86 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2776116 | 0.86 | GPR119 (0.69) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL69206 | 0.85 | KDM1A (0.56) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3160552 | 0.85 | GPR119 (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL29964428 | 0.85 | GPR119 (0.59) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197692-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2010-08-05 | — | — | US | disclosed |
| EP-2178884-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2010-04-28 | — | — | EP | disclosed |
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| US-20090270434-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | LEBLANC YVES | 2009-10-29 | — | — | US | disclosed |
| US-20090270434-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | LEBLANC YVES | 2009-10-29 | — | — | US | disclosed |
| US-20090270434-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | LEBLANC YVES | 2009-10-29 | — | — | US | disclosed |
| US-7582633-B2 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA L.L.C. (CA) | 2009-09-01 | — | — | US | disclosed |
| US-7582633-B2 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA L.L.C. (CA) | 2009-09-01 | — | — | US | disclosed |
| US-7582633-B2 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA L.L.C. (CA) | 2009-09-01 | — | — | US | disclosed |
| EP-2076509-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009012573-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-01-29 | — | — | WO | disclosed |
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-07-31 | — | — | US | disclosed |
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-07-31 | — | — | US | disclosed |
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-07-31 | — | — | US | disclosed |
| WO-2008089580-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008046226-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182838-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | GPR119 61/4885PDE4D 3315/4885PDE4B 3430/4885 |
| US-20100197692-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, CPT1A | GPR119 57/4885PDE4D 3780/4885PDE4B 3820/4885 |
| US-20090270434-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | GPR119 61/4885PDE4D 3315/4885PDE4B 3430/4885 |
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | GPR119 69/4885PDE4D 3184/4885PDE4B 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.